Philippe Mathurin

Philippe Mathurin's AcademicInfluence.com Rankings

Philippe Mathurin

Computer Science

#6193

World Rank

#6529

Historical Rank

Computational Linguistics

#1020

World Rank

#1034

Historical Rank

Machine Learning

#1931

World Rank

#1957

Historical Rank

Artificial Intelligence

#2180

World Rank

#2217

Historical Rank

computer-science Degrees

Philippe Mathurin

Mathematics

#6450

World Rank

#8927

Historical Rank

Measure Theory

#1352

World Rank

#1700

Historical Rank

mathematics Degrees

Download Badge

Computer Science
Mathematics

Philippe Mathurin's Degrees

PhD Computer Science Université Paris Cité
Masters Computer Science Université Paris Cité
Bachelors Mathematics Université Paris Cité

Similar Degrees You Can Earn

Why Is Philippe Mathurin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Philippe Mathurin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration (1996) (733)
Early liver transplantation for severe alcoholic hepatitis. (2011) (622)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
Hepatorenal syndrome (1996) (620)
The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids (2007) (593)
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. (2015) (587)
Alcoholic liver disease: mechanisms of injury and targeted treatment (2015) (582)
EASL clinical practical guidelines: management of alcoholic liver disease. (2012) (570)
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) (2019) (535)
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. (2013) (522)
Impact of hepatitis B and C virus on kidney transplantation outcome (1999) (517)
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. (1995) (468)
Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. (2009) (450)
A comparison of fibrosis progression in chronic liver diseases. (2003) (447)
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial (2013) (443)
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. (2017) (403)
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. (2018) (398)
A double‐blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis (2004) (387)
Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data (2010) (378)
Alcoholic liver disease (2018) (366)
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease (2019) (365)
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. (1992) (354)
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (2019) (343)
A histologic scoring system for prognosis of patients with alcoholic hepatitis. (2014) (337)
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3‐ and 6‐month periodicities (2011) (334)
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity (1998) (327)
Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. (2002) (322)
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. (2016) (304)
Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. (2009) (294)
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. (2011) (285)
A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) (283)
Exacerbation of alcoholic liver injury by enteral endotoxin in rats (2000) (283)
Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. (2017) (277)
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. (1999) (267)
Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. (1996) (261)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. (2018) (249)
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
Beta‐adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta‐analysis (1997) (242)
Trends in the management and burden of alcoholic liver disease (2015) (232)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (2021) (230)
Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis (2015) (226)
Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. (2017) (215)
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. (2005) (213)
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data (2014) (211)
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. (2020) (210)
Albumin Dialysis With a Noncell Artificial Liver Support Device in Patients With Acute Liver Failure (2013) (210)
In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. (1997) (204)
Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study (2014) (201)
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. (2013) (197)
Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone (2003) (192)
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. (2018) (170)
Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. (2008) (163)
Alcoholic hepatitis. (2009) (158)
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). (2015) (157)
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis (2007) (156)
[Magnetic resonance imaging of the brain]. (1988) (155)
The evolution of severe steatosis after bariatric surgery is related to insulin resistance. (2006) (151)
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. (2014) (142)
Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis. (2015) (133)
Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features (2007) (128)
Management of alcoholic hepatitis. (2012) (127)
Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data (2012) (127)
Predicted effects of treatment for HCV infection vary among European countries. (2012) (126)
Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta‐analysis (2005) (125)
Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis (2015) (124)
Effect of binge drinking on the liver: an alarming public health issue? (2009) (121)
Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study* (2002) (121)
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. (2018) (121)
Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis (2012) (121)
Impact of Impaired Aerobic Capacity on Liver Transplant Candidates (2008) (119)
Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study (2017) (117)
Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. (2000) (116)
Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. (2018) (115)
[Alcoholic hepatitis]. (2018) (110)
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child‐Pugh score (2011) (106)
Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis (2020) (106)
Original Articles: Liver Failure and Liver DiseaseEarly change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone (2003) (100)
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. (2017) (100)
Recurrent Alcoholic Cirrhosis In Severe Alcoholic Relapse After Liver Transplantation: A Frequent and Serious Complication (2015) (100)
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity (2011) (96)
Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma (2003) (96)
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort) (2015) (95)
Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (2019) (93)
8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (2012) (93)
1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY (2012) (92)
Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. (2011) (92)
Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. (1997) (91)
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. (2019) (87)
ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. (2013) (85)
Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease (1998) (84)
A Multidimensional Case‐Control Study of Dietary, Alcohol, and Tobacco Habits in Alcoholic Men with Chronic Pancreatitis (1995) (82)
Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. (2010) (79)
Interferon for interferon naive patients with chronic hepatitis C. (2002) (77)
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir) (2016) (76)
Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review. (2021) (75)
Evaluation of amantadine in chronic hepatitis C: a meta-analysis. (2004) (73)
Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. (2006) (72)
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. (2018) (69)
Perspectives on Treatment for Nonalcoholic Steatohepatitis. (2016) (67)
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). (2014) (64)
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting (2019) (64)
Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. (2002) (63)
Vasospasm after subarachnoid hemorrhage: diagnosis with MR angiography. (2000) (62)
The negative impact of HBV/HCV coinfection on cirrhosis and its consequences (2017) (59)
Prednisone‐interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis (1994) (59)
Assessing the cost-effectiveness of hepatitis C screening strategies in France. (2018) (58)
Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. (2008) (57)
Relevance of the ISGLS Definition of Posthepatectomy Liver Failure in Early Prediction of Poor Outcome After Liver Resection: Study on 680 Hepatectomies (2014) (57)
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)‐related cirrhosis aware of their HCV status improves survival: A modeling approach (2014) (55)
Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis (2019) (55)
Diagnosis of intracranial aneurysms: accuracy of MR angiography at 0.5 T. (1998) (55)
GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (54)
Interferon for acute hepatitis C. (2001) (54)
Alcohol‐Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study (2019) (53)
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort) (2015) (53)
Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes (2017) (48)
Intestinal Virome in Patients With Alcoholic Hepatitis (2020) (47)
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity (2018) (47)
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients (2018) (47)
Facet joint arthrography in lumbar spondylolysis. (1981) (46)
Patients with acute liver failure listed for superurgent liver transplantation in France: Reevaluation of the clichy‐villejuif criteria (2015) (46)
Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis (2018) (45)
Randomised clinical trial: enteral nutrition does not improve the long‐term outcome of alcoholic cirrhotic patients with jaundice (2012) (45)
Bariatric surgery for curing NASH in the morbidly obese? (2013) (45)
Meta‐analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV‐2 and ‐3 patients (2012) (44)
1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL (2012) (44)
Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease (2017) (44)
Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. (2009) (43)
Alcohol-related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. (2018) (43)
Histological features predictive of liver fibrosis in chronic hepatitis C infection. (1996) (42)
A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso) (2017) (42)
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis (2017) (42)
NOD2: a potential target for regulating liver injury (2008) (42)
Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. (2019) (42)
Hepatitis C virus therapy to date (2008) (41)
Corticosteroids for alcoholic hepatitis--what's next? (2005) (41)
Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis (2018) (41)
IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. (2002) (41)
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. (2012) (41)
Assessing bone status in patients awaiting liver transplantation. (2011) (41)
Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. (2017) (40)
Prevalence of renal abnormalities in chronic HBV infection: The HARPE study (2015) (40)
Is alcoholic hepatitis an indication for transplantation? Current management and outcomes (2005) (40)
LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather* (2015) (38)
Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: A case‐control study (2007) (37)
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. (2020) (36)
Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control. (2010) (35)
Anti‐viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy (2011) (33)
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (2020) (32)
Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. Results of a multicenter prospective study. (2005) (32)
Combined alcoholic and non-alcoholic steatohepatitis (2020) (32)
Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT‐based surveillance (2020) (31)
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France (2009) (31)
β-Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. (2018) (31)
Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma (2006) (31)
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication (2018) (30)
LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather (2015) (30)
Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. (1993) (29)
Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences (1999) (29)
Conversion to sirolimus: A useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient (2006) (29)
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). (2011) (29)
Mycophenolate Mofetil Monotherapy for Severe Side Effects of Calcineurin Inhibitors Following Liver Transplantation (2009) (28)
The immunology of fibrogenesis in alcoholic liver disease. (2009) (27)
Brief Report: Genetics of Alcoholic Cirrhosis—GenomALC Multinational Study (2015) (27)
Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. (2012) (27)
Liver Transplantation for Alcoholic Liver Disease. (2013) (27)
μ-Opioid receptor activation prevents acute hepatic inflammation and cell death (2007) (27)
Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. (2020) (26)
1021 GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE (2012) (26)
IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. (2020) (26)
Cost‐effectiveness and budget impact of interferon‐free direct‐acting antiviral‐based regimens for hepatitis C treatment: the French case (2016) (26)
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study (2020) (25)
29 EARLY TRANSPLANTATION IMPROVES SURVIVAL OF NON-RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A CHALLENGE TO THE 6 MONTH RULE OF ABSTINENCE (2010) (25)
Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors (2020) (24)
CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (24)
Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease (2019) (24)
Liver transplantation in patients with alcohol-related liver disease: current status and future directions. (2020) (24)
IDENTIFICATION OF OPTIMAL THERAPEUTIC WINDOW FOR STEROID USE IN SEVERE ALCOHOL-ASSOCIATED HEPATITIS: A WORLDWIDE STUDY. (2021) (23)
Binding of apolipoprotein A‐I and acetaldehyde‐modified apolipoprotein A‐I to liver extracellular matrix (1996) (23)
Liver transplantation for patients with alcoholic hepatitis (2017) (23)
Prevalence of cholelithiasis according to alcoholic liver disease: a possible role of apolipoproteins AI and AII. (1995) (22)
French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. (2018) (22)
Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding (2015) (22)
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis (2011) (21)
Early liver transplantation for corticosteroid non-responders in acute severe autoimmune hepatitis: the SURFASA score. (2021) (21)
Mesenteric adenitis and portal vein thrombosis due to Fusobacterium nucleatum. (2004) (21)
Peroxisome Proliferator-Activated Receptors in HCV-Related Infection (2009) (21)
Recalibrated MELD and hepatic encephalopathy are prognostic factors in cirrhotic patients with acute variceal bleeding (2018) (21)
Modelling the past, current and future HCV burden in France: detailed analysis and perspectives (2009) (20)
Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. (2020) (20)
Publisher Correction: Alcoholic liver disease (2018) (19)
Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis (2021) (19)
Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study (2017) (18)
Alcoholic liver injury and apoptosis--synopsis of the symposium held at ESBRA 2001: 8th Congress of the European Society for Biomedical Research on Alcoholism, Paris, September 16, 2001. (2002) (18)
Fatal hemophagocytic syndrome related to human herpesvirus-6 reinfection following liver transplantation: a case report. (2008) (18)
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. (2021) (18)
Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. (2019) (18)
Quantification of apolipoprotein A‐I and B messenger RNA in heavy drinkers according to liver disease (1996) (18)
Spinal dural arterio-venous fistula: an underdiagnosed disease? (1997) (17)
MRI assessment of unsuspected dural sinus thrombosis (2004) (17)
Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules. (2019) (16)
Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. (2020) (16)
Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. (2020) (16)
Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis (2001) (16)
Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis. (2021) (16)
Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study. (2018) (16)
Impact of a first study of early transplantation in acute alcoholic hepatitis: Results of a nationwide survey in french liver transplantation programs (2018) (16)
HCV burden in Europe and the possible impact of current treatment. (2013) (16)
Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach. (2014) (16)
49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188) (2013) (15)
34 PROSPECTIVE SCREENING OF INFECTION IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH STEROIDS: EARLY RESPONSE TO THERAPY IS THE KEY FACTOR (2008) (15)
Alcohol, liver disease, and transplantation: shifting attitudes and new understanding leads to changes in practice (2018) (15)
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. (2022) (15)
220 PREDICTIVE FACTORS OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH FULMINANT AND SUBFULMINANT HEPATIC FAILURE: RESULTS FROM A RANDOMIZED CONTROLLED MULTICENTER TRIAL (2009) (14)
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference (2018) (14)
Apolipoprotein A1 and hepatic fibrosis. (1995) (14)
2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS (2010) (14)
Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage (2019) (14)
Prothrombin index decrease: a useful and reliable marker of extensive fibrosis? (2002) (14)
Treatment of severe forms of alcoholic hepatitis: Where are we going? (2008) (14)
Non‐virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort (2019) (14)
Peroxisome Proliferator-Activated Receptors in HBV-Related Infection (2009) (14)
Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin (1997) (13)
Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. (2018) (13)
Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. (2005) (13)
Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. (1996) (13)
Management of alcohol‐related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines (2022) (13)
Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-I by hepatocytes. (1996) (13)
Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis (2016) (13)
Treatment of chronic hepatitis C by interferon for longer duration than six months (1996) (12)
Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. (2019) (12)
Recurrence of varicocele after spermatic vein embolization in young patients: radiological aspect. (1995) (12)
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease (2022) (12)
Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. (2015) (12)
A 2‐log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study (2009) (12)
Extensive portal vein thrombosis related to abdominal trauma. (2006) (12)
Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS‐FANTASIO study) (2019) (12)
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis (2018) (11)
micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. (2007) (11)
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors (2022) (10)
Juxtamedullary Spinal Accessory Nerve Neurinoma (1992) (10)
Impact of steatosis and inflammation definitions on the performance of NASH tests (2017) (10)
Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study (2015) (10)
75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS (2008) (10)
P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER (2015) (9)
Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis. (2001) (9)
[Lateral neck paraganglioma: diagnostic imaging and preoperative embolization]. (1993) (9)
The use of corticosteroids in severe alcohol hepatitis: we need to look beyond this controversy. (2010) (9)
Endpoints and patient stratification in clinical trials for alcoholic hepatitis. (2019) (9)
A patient with alcoholic liver failure referred for liver transplantation (2007) (9)
Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis: a prospective study (2017) (9)
Hepatic cirrhosis and kidney transplantation outcome. (1997) (9)
Treatment by aspiration of brain abscesses (2005) (9)
Spontaneous Cerebellar Hematoma (1990) (9)
Primary sarcoma of the liver and transplantation: a case study and literature review (2009) (8)
Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community‐based cohort (2022) (8)
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis (2021) (8)
Management of alcohol dependence in transplant candidates: We are far away from the objective line (2011) (8)
Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis? (2017) (8)
Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease. (2016) (8)
Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases (2021) (8)
[Pro-inflammatory cytokines in the pathogenesis of alcoholic hepatitis]. (1998) (8)
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study. (2021) (8)
47 A MULTICENTRIC, DOUBLE-BLIND, RANDOMISED- CONTROLLED TRIAL (RCT) OF HIGH DOSE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) (2009) (8)
A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. (2020) (8)
Magnetic resonance imaging of intrasellar lesions. (1990) (8)
"Dual aetiology fatty liver disease": a recently proposed term associated with potential pitfalls. (2020) (7)
Anticoagulation Therapy May Reverse Biliary Abnormalities Due to Acute Portal Thrombosis (2006) (7)
Effect of terlipressine (Glypressine®) on hepatorenal syndrome (HRS) in cirrhotic patietns: Results of a pilot study (1998) (7)
101 TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUSINFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE (2013) (7)
1357 PENTOXIFYLLINE DOES NOT IMPROVE SHORT-TERM SURVIVAL IN SEVERE ALCOHOLIC HEPATITIS IN COMBINATION WITH CORTICOSTEROIDS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (2012) (7)
Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance (2021) (7)
O85 SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188) (2014) (7)
[Isolated ascites revealing a hypothyroidism. Study of 2 cases]. (1998) (7)
A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases (2016) (7)
Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice (2020) (7)
Interest and necessity of combined neuroradiological and neurosurgical treatment in some cases of dural arterio-venous fistulae (2005) (7)
Therapeutic management of alcoholic hepatitis. (2015) (7)
[Juxtabulbar neurinoma of the spinal accessory nerve]. (1992) (6)
New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort) (2016) (6)
OC-17 HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach (2011) (6)
21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS (2009) (6)
MRI of Pituitary Adenomas: Role of Gd-DTPA (1989) (6)
Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study) (2021) (6)
[Membranous glomerulonephritis complicating hepatocellular carcinoma]. (2004) (6)
Cervical myelopathy: MRI evaluation of cord compression. (1990) (6)
Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH) (2022) (6)
Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon‐alpha‐2b‐ribavirin combination therapy (2010) (6)
Acute hepatitis during hypersensitivity syndrome due to midecamycin. (1997) (6)
Prednisolone markedly improves short-term survival of patients with severe biopsy-proven alcoholic hepatitis. A double blind randomized bicenter trial (1991) (6)
Hydrocephalus in Guillain-Barré syndrome. (1991) (6)
201 CORTICOSTEROIDS IMPROVE 28-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS: INDIVIDUAL DATA ANALYSIS OF THE LAST 5 RANDOMIZED CONTROLLED TRIALS (2009) (6)
122 HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH (2010) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
[Daily life, pregnancy, and quality of life after liver transplantation]. (2009) (5)
Early liver transplantation for acute alcoholic hepatitis: we can't say no. (2021) (5)
Efficacy of long term recombinant interferon-alfa in patients with chronic hepatitis C. A clinical, biological, histological and immunohistological study. (1991) (5)
938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (5)
Contributory aspects of MRI in the evaluation of basal encephaloceles. (1989) (5)
W1806 Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis (2009) (5)
950 TOLERANCE AND EFFICACY OF THE MARS SYSTEM IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS NON-RESPONDERS TO STEROIDS: A PILOT STUDY (2008) (5)
[Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects]. (2008) (5)
Changes of serum‐associated fucosylated glycoproteins and changes in glycosylation of IgA in human cirrhosis (2009) (5)
Real life experience of mycophenolate mofetil monotherapy in liver transplant patients. (2020) (5)
Medical Progress Alcoholic Hepatitis (2009) (5)
[Clinical aspects and surgical treatment of carotid body tumors]. (1985) (5)
Should patients with alcoholic hepatitis be considered for liver transplantation? (2015) (5)
[Multiple cranial nerve involvement associated with tentorial pachymeningitis of granulomatous type]. (1988) (5)
Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. (2022) (5)
The Tolerability of SOF/VEL for 12 Weeks in >1,000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis (2016) (4)
Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin. (2011) (4)
[Hepatitis B viral infection treated with lamivudine during pregnancy]. (2009) (4)
The prognostic impact of cirrhosis on patients receiving maintenance haemodialysis (2019) (4)
Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. (2002) (4)
THU-340-Epidemiology of NAFLD and advanced fibrosis in the French general population: A population-based cohort study in 118, 664 subjects (NASH-CO study) (2019) (4)
[Choroid-plexus Papilloma of the Lateral Ventricle Without Generalized Hydrocephalus] (1988) (4)
Final analysis of European patients from the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline characteristics and staging systems. (2014) (4)
[Adult-onset Still's disease and hepatic angiosarcoma, a fortuitous association or a paraneoplastic syndrome: a case-report]. (2008) (4)
Partial graft recovery following eradication of hepatitis E virus infection after successful islet allograft transplantation (2011) (4)
P0745 : EQ-5D utility index in French patients with chronic hepatits C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage (2015) (4)
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort (2019) (4)
[External and internal hydrocephalus caused by an arteriovenous malformation in an infant]. (1986) (3)
[Celiac disease and liver involvement]. (2003) (3)
PREDNISOLONE IN SEVERE ALCOHOLIC HEPATITIS. AUTHOR'S REPLY (1992) (3)
Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study (2022) (3)
Sphenopharyngeal meningoencephalocele: unusual clinical and radiologic features. (1989) (3)
[Epidemiology of alcoholic liver disease and new challenges]. (2009) (3)
P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather (2015) (3)
Early liver transplantation for severe alcoholic hepatitis not responding to medical treatment: results of the French-Belgian prospective study QuickTrans (2020) (3)
1034 REAL-WORLD MANAGEMENT OF HCC WITH SORAFENIB AND TACE IN EUROPE FROM GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HCC AND OF ITS TREATMENT WITH SORAFENIB) (2012) (3)
1358 A NEW FORMULA OF THE LILLE MODEL USING INR (2012) (3)
[Alcohol and the liver]. (2009) (3)
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV (2021) (3)
220 ACETAMINOPHEN THERAPEUTIC MISADVENTURE: A PROSPECTIVE STUDY (2008) (3)
[Corticosteroid therapy in acute severe alcoholic hepatitis: the end of a controversy?]. (1998) (3)
1024 EFFICACY AND SAFETY OF THE COMBINATION OF ENTECAVIR (ETV)-TENOFOVIR (TDF) IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A NATIONWIDE, RETROSPECTIVE STUDY (2010) (3)
Transcatheter aortic valve replacement (TAVR) as bridge therapy restoring eligibility for liver transplantation in cirrhotic patients (2020) (3)
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. (2020) (3)
[Spontaneous hematoma of the cerebellum]. (1990) (3)
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort (2016) (3)
[Treatment of chronic hepatitis C and alcohol consumption]. (2002) (3)
Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection (2019) (3)
160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results (2008) (3)
Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort) (2016) (3)
Pharmacological treatment for alcoholic hepatitis and cirrhosis: present practice and future strategies (2002) (3)
The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population‐based follow‐up study (NASHCO) (2022) (3)
117 SPONTANEOUS DECREASE IN LIVER INJURY DOES NOT STRONGLY PREDICT EVOLUTION OF PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS (2013) (2)
Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis (2022) (2)
[Therapeutic misadventure with acetaminophen in alcoholics]. (2009) (2)
La mésaventure thérapeutique au paracétamol chez le buveur excessif (2009) (2)
[Problems with therapeutic acetaminophen use in excessive drinkers]. (2006) (2)
[Acute alcoholic hepatitis. Management practices for 2007]. (2008) (2)
809 IMMEDIATE OR DELAYED TREATMENT INITIATION WITH “PREVIR” CONTAINING REGIMENS IN HCV-INFECTED NAIVE GENOTYPE 1 (G1) PATIENTS WITHOUT SEVERE FIBROSIS? A COST-EFFECTIVENESS ANALYSIS (ANRS N°12188) (2013) (2)
Metabolic outcome 5 years after restrictive or malabsorptive bariatric surgery, a prospective comparative trial (2005) (2)
Multiple Cranial Nerve Involvement Associated With Granulomatous Tentorial Pachymeningitis (1988) (2)
Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites. (2006) (2)
[Non alcoholic steatohepatitis: the future in hepatology?]. (2002) (2)
Comparison of Binary Predictive Scoring Systems of Posthepatectomy Liver Failure: A Response. (2017) (2)
[Alcohol, metabolic syndrome and obesity: impact on treatment efficacy]. (2007) (2)
[Inflammatory bowel disease and latent thrombocythemia: a novel cause of hepatic vein thrombosis?]. (2004) (2)
[Papilloma of the choroid plexus of the lateral ventricle without generalized hydrocephalus]. (1988) (2)
Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C (2013) (2)
Erratum: Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA (Gastroenterology (2014) 146 (1240-1248)) (2015) (2)
501 PROGNOSTIC SCORES ARE EFFICIENT IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS: COMPARISON OF AVAILABLE MODELS (2011) (2)
[Reversible External and Internal Hydrocephalus, Due To An Arteriovenous Malformation in An Infant] (1986) (2)
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis (2021) (2)
[Varicocele: treatment via percutaneous approach]. (1994) (2)
The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis (2021) (2)
1362 THE AVAILABILITY OF DIRECT ACTING ANTIVIRALS (DAA) IN 2012: A FRENCH MODEL-BASED ANALYSIS OF THE INCREASED NUMBER OF PATIENTS TREATED FOR CHRONIC HCV INFECTION (2011) (2)
Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus (2020) (2)
2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256 (2010) (1)
246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis (2019) (1)
925 SAFETY AND TOLERABILITY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBeAg NEGATIVE AND POSITIVE PATIENTS INFECTED WITH CHRONIC HEPATITIS B (CHB) (2009) (1)
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in HCV Infected Patients Previously Treated with Placebo: Results of the Deferred Treatment Study (GS-US-342-1446 Study) (2016) (1)
O139 ALCOHOLIC HEPATITIS RESISTANT TO MEDICAL THERAPY IS CHARACTERIZED BY AN ALTERED DIFFERENTIATION OF HEPATIC PROGENITORS UNDER THE INFLUENCE OF EXTRACELLULAR MATRIX (2014) (1)
Erratum to: "IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis". (2021) (1)
Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial) (2011) (1)
The Interest of New Investigation Techniques in Toxicology (1987) (1)
6 BARIATRIC SURGERY AN EFFICIENT TREATMENT FOR PATIENT WITH STEATOHEPATITIS (2012) (1)
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B (2022) (1)
Hepatitis C virus infection is associated with impaired expression and transcriptional activity of the peroxisome proliferator activated receptor alpha (2004) (1)
Combination Therapy in Severe Alcoholic Hepatitis— Doesn't Really Work (2013) (1)
Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis. (2023) (1)
Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study) (2020) (1)
[Alcohol, steatohepatitis, insulin resistance and hepatitis C]. (2008) (1)
T1013 A Multicentric, Double-Blind, Randomized Placebo-Controlled Trial of High Dose Ursodeoxycholic Acid in Patients with Non-Alcoholic Steatohepatitis (NASH) (2009) (1)
Lung Infection Affects Access to Treatment and Short-Term Outcome in Patients With Severe Alcohol-Related Hepatitis Treated With Corticosteroids (2022) (1)
On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1–6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies (2016) (1)
892 - Transcriptional Dysregulation of Inflammatory Gene Networks in Alcoholic Hepatitis is Associated with Genomewide Reconfiguration of Epigenetic States (2018) (1)
66 PROSPECTIVE EVALUATION OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): DOES CHILD SCORE B INFLUENCE SAFETY? (2009) (1)
[The value of preoperative embolization and high-resolution tomodensitometry in the surgery of tympanojugular glomus tumors]. (1984) (1)
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort (2022) (1)
CYTOKINES AND ALCOHOLIC HEPATITIS (1998) (1)
Liver Transplantation for Severe Alcoholic Hepatitis: Where Are We Now? (2018) (1)
626 ASSESSMENT OF RESPONSE TO SORAFENIB IN HEPATOCELLULAR CARCINOMA: PROGNOSTIC VALUE OF TUMORAL DENSITY AND ARTERIAL ENHANCEMENT MEASUREMENTS IN TARGET LESIONS (2011) (1)
Long-term results of the first study of early liver transplantation for alcoholic hepatitis (2020) (1)
123 EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN IN HCV GENOTYPE 1 NON-RESPONDERS: AN INTERIM ANALYSIS OF THE SYREN TRIAL (2009) (1)
32 SERUM PROTEIN PROFILING OF ALCOHOLIC HEPATITIS USING MASS SPECTROMETRY (SELDI-TOF MS PROTEINCHIP): IDENTIFICATION OF A BIOMARKER OF RESPONSE TO CORTICOSTEROIDS (2008) (1)
A tool to predict progression of non‐alcoholic fatty liver disease in severely obese patients (2020) (1)
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort (2022) (1)
868 TREATMENT WITH TELAPREVIR-BASED THERAPY AFTER EXPOSURE TO PEG-IFN/RBV IN THE REALIZE STUDY: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY (2013) (1)
Le bilan radiologique de la lombalgie. (1981) (1)
Impaired liver expression of the peroxysome proliferator-activated receptor (PPAR)-A modulates liver steatosis and inflammation during hepatitis C virus (HCV) infection (2002) (1)
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity (2018) (1)
396 ASSESSMENT OF LIVER STIFFNESS (LS) IN THE RELAPSE OF ALCOHOLIC LIVER DISEASE (RALD) AFTER LIVER TRANSPLANTATION (LT) (2010) (0)
[The Vascular Tumors of the Jaw Bones - Progress Report] (1989) (0)
W1814 Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB) (2009) (0)
Hepatocyte Dedifferentiation Profiling In Alcohol-Related Liver Disease Identifies CXCR4 As A Driver Of Cell Reprogramming (2023) (0)
Reply to: “HCV infection, HOMA index and sustained virological response: The step we need to take before moving forward” (2012) (0)
NAFLD, Obesity, and Bariatric Surgery (2013) (0)
1163 IMPACT OF HBV AND HCV IN KIDNEY TRANSPLANTED PATIENTS: ACTUALIZATION OF PREVALENCE AND PROGNOSTIC DATA (2011) (0)
[47] THE LONG TERM BENEFITS OF BARIATRIC SURGERY CORRELATED TO INSULIN RESISTANCE: A PROSPECTIVE STUDY WITH 5 YEARS OF FOLLOW UP (2007) (0)
510 PREVENTION OF LIVER ISCHEMIA/REPERFUSION INJURY BY MODULATING INTESTINAL FLORA: AN ATTRACTIVE APPROACH (2011) (0)
855 DIAGNOSTIC VALUE OF BIOMARKERS (FIBROTEST, ACHTEST, STEATOTEST AND NASHTEST) FOR THE PREDICTION OF LIVER INJURY IN 494 PATIENTS WITH SEVERE OBESITY (2011) (0)
O017 : Effectiveness of treatment initiation based on fibrosis stage assessed by methods of fibrosis diagnosis in terms of 5-year incidence of morbi-mortality (2015) (0)
[582] VIRAL KINETICS CAN PREDICT VIROLOGICAL RESPONSE IN HCV PATIENTS WITH NORMAL ALT TREATED WITH PEGYLATED IFN ALFA-2b AND RIBAVIRIN: A PROSPECTIVE STUDY (2007) (0)
P1087 : Prediction of death as a continuum of risk of mortality in severe alcoholic hepatitis based on baseline and dynamic models (2015) (0)
Estimated risk reduction of mortality and transplantation with bezafibrate in patients with PBC and inadequate response to UDCA: application of the UK-PBC and Global PBC risk scores to the BEZURSO trial (2018) (0)
Treatment Targets and Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Summary of AALSD Trend Conference in NASH (2020) (0)
Sneddons Syndrome - a Rare Cause of Diffuse Vasculopathy - a Case-report With Review of the Literature (1990) (0)
Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort) (2016) (0)
A Biliary Milestone: Functional Expression of the Human Bile Salt Export Pump (2002) (0)
Sneddon's syndrome: a rare cause of diffuse vasculopathy. A case report with review of the literature. (1990) (0)
Cirrhosis impacts outcome of hemodialyzed patients and should lead to consider spontaneous liver-kidney transplantation (2017) (0)
538 Bacterial Receptor NOD1 Regulates in the Neutrophil Migration Machinery During Liver Injury (2009) (0)
[Effects of bariatric surgery on the liver]. (2005) (0)
Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France (2017) (0)
Lumbar Discography By Lateral Approach (1980) (0)
Usefulness of phosphatidylethanol and urinary ethyl glucuronide to monitor alcohol abstinence in patients awaiting liver transplantation (2020) (0)
1301 BARIATRIC SURGERY CAN BE PROPOSED TO MORBID OBESE HIGHLY SELECTED WITH COMPENSATED CIRRHOSIS (2012) (0)
Transcatheter arterial chemoembolization (TACE) followed by conformal radiotherapy versus TACE alone for hepatocellular carcinoma: a western controlled trial (2022) (0)
Unusual involvement in a case of brain tumor. (1987) (0)
A model to predict drinking population at-risk of liver disease in France: a tool for decision-making public health policies (2022) (0)
635 Efficacy and Safety of the Combination of Entecavir (ETV)-Tenofovir (TDF) in the Treatment of Chronic Hepatitis B (CHB): A Nationwide, Retrospective Study (2010) (0)
252 2-LOG DROP IN VIRAL LOAD AT ONE MONTH: A NEW STOPPING RULE IN RELAPSERS AND NON-RESPONDERS HCV PATIENTS RE-TREATED WITH PEGYLATED-IFN AND RIBAVIRIN? (2010) (0)
THU-297-Prediction of NAFLD progression according to duration of exposure to obesity and diabetes: New approach to adapt therapeutic and research strategies (2019) (0)
28. Alcoholic Liver Disease (2010) (0)
Second Interim Analysis of the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) Study According to Disease Stage (2012) (0)
Corticosteroids efficacy in severe alcoholic hepatitis (AH): Retrospective analysis of individual data from the American ANF French randomized contolled trials (2000) (0)
P-0073 GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its Treatment eith Sorafenib): European Interim Safety and Dosing Subanalysis (2012) (0)
[Arthrography and computerized tomography in the radiological assessment of the temporomandibular joint]. (1986) (0)
Hepatitis C and NAFLD as Main Causes of Liver-Related Morbidity and Mortality in the French General Population: A Nationwide Study (NASH-CO Study) (2022) (0)
What Are the Best Diagnostic Modalities for Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis? A Summary of AALSD Trend Conference in NASH (154/120) (2020) (0)
24: The evolution of severe steatosis after bariatric surgery is related to insulin resistance (2006) (0)
Astrocytoma of the cervical medulla. (1990) (0)
P1093 : Characterization of acetaminophen therapeutic misadventure: A single centre experience (2015) (0)
SAT-490-No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort (2019) (0)
A Case of Miliary Tuberculosis in Chest and Brain (1982) (0)
92 Prediction of mortality in severe alcoholic hepatitis: Validation of lille model and comparison to other prognostic scores (2006) (0)
PIN4 A MARKOV MODELTO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMALTRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY (2008) (0)
[35] LIVER TRANSPLANTATION (LT) FOR CHOLANGIO-CARCINOMA (CC): LONG-TERM RESULTS IN 42 PATIENTS (2007) (0)
[153] MYCOPHENOLIC ACID (MPA) AUC(0-12h) IN STABLE LIVER TRANSPLANT PATIENTS TREATED WITH A MONOTHERAPY OF MYCOPHENOLATE MOFETIL (MMF) FOR CALCINEURIN INHIBITORS (CNI) INDUCED NEPHROTOXICITY (2007) (0)
405 HARPE STUDY: PREVALENCE OF RENAL ABNORMALITIES IN CHRONIC HBV INFECTION (2013) (0)
[30] INVOLVEMENT OF NOD SIGNALLING IN HEPATOCYTE AND IMMUNE CELLS DURING HEPATITIS (2007) (0)
Usefullness of routine analysis of ascites fluid at the time of therapeutic paracentesis in asymptomatic cirrhotic out patients (2002) (0)
REPLY: (2021) (0)
Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. (2021) (0)
Severe alcoholic hepatitis (2012) (0)
203 TAFI DEFICIENCY AND ENDOTHELIAL CELL ACTIVATION PLAY A KEY ROLE IN COAGULATION DISORDERS OF PATIENTS WITH SEVERE ACUTE-ON-CHRONIC LIVER FAILURE TREATED BY MARS® SYSTEM (2009) (0)
ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts (2022) (0)
715 BASELINE GENOTYPE AND HBSAG WERE FOUND TO HAVE SIGNIFICANT ASSOCIATION WITH HBEAG SEROCONVERSION FOLLOWING UP TO 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE TREATMENT (2011) (0)
703 BACTERIAL RECEPTOR NOD1 REGULATES THE NEUTROPHIL MIGRATION MACHINERY DURING LIVER INJURY (2009) (0)
1316 METABOLIC COMORBIDITIES IN A LARGE FRENCH REAL-LIFE COHORT OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (2012) (0)
MRI of Pituitary Adenomas: Comparison with CT (1989) (0)
661 ULTRASONOGRAPHIC (US) SCREENING OF HEPATOCELLULAR CARCINOMA (HCC) IN COMPENSATED CIRRHOSIS DUE TO HEPATITIS C VIRUS (HCV) IMPROVES SURVIVAL: A MODELING APPROACH (2013) (0)
[Interview: questions to Philippe Mathurin]. (2006) (0)
606 ANTI-VIRAL THERAPY IN HAEMODIALYZED HCV PATIENTS: EFFICACY, TOLERANCE AND TREATMENT STRATEGY (2009) (0)
P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER (2015) (0)
Untreated alcohol use disorder in people who inject drugs: a major barrier to HCV treatment uptake (2019) (0)
Cost-Effectiveness and Budget Impact of Interferon-Free Direct-Acting Antiviral (DAA)-Based Regimens for Chronic Hepatitis C Treatment. The French Case (2016) (0)
Benefits of tailored HCC surveillance programs on case-fatality rate and cancer-specific mortality using a modelling approach (2022) (0)
[Pathology of the foramen cecum. Apropos of 2 cases of nasal cysts of dermoid origin and 1 case of intranasal glioma]. (1983) (0)
Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: a retrospective database analysis. (2023) (0)
[Intracerebral tumor calcifications unrecognized by MRI]. (1997) (0)
Continuation of metformin use after a diagnosis of cir- rhosis significantly improved survival of patients with type II diabetes (DM) (2013) (0)
1854P Multicentric, comparative, retrospective study on the safety and efficacy of conventional chemotherapy in cirrhotic patients with gastrointestinal cancer (2021) (0)
Serum transferrin levels reflect hepatocyte nuclear factor 4 alpha activity in the liver (2020) (0)
Pictoral essay neck paragangliomas: diagnosis and presurgical embolization (1993) (0)
Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies (2016) (0)
Subject Index Vol. 31, 1991 (1991) (0)
Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial (2021) (0)
Combination of the Lille model with baseline scores is useful to predict mortality in severe alcoholic hepatitis: a confirmation study in a large database of patients (2018) (0)
Risk factors, treatment patterns and survival of patients with incident hepatocellular carcinoma in France: A retrospective data analysis. (2021) (0)
[Vascular tumors of the jaw. Analysis]. (1989) (0)
[Alcoholic hepatitis: pathophysiological data and therapeutic perspectives]. (2004) (0)
Ascite : Orientation diagnostique (2005) (0)
[Cirrhosis: new concepts and great therapeutic progresses]. (2005) (0)
Guidelines EASL Clinical Practice Guidelines : Management of alcohol-related liver disease q European Association for the Study of the Liver ⇑ (2018) (0)
Angiosarcome hépatique et hépatite fulminante: une association exceptionnelle (2009) (0)
Blood neutrophil fbnctions and cytokine release in hepatitis effect of corticosteroids severe alcoholic (2000) (0)
Transient Elastography and Combination of Fibrotest® and Transient Elastography for Diagnosis of Advanced Fibrosis and Cirrhosis in Patients with Alcoholic Liver Disease: A Prospective Multicenter Cohort Study (2016) (0)
1350 GASTRIC BYPASS IS EFFICIENT ON MEBOLIC AND LIVER STEATOSIS AFTER LAPAROSCOPIC GASTRIC BANDING RELAPSE (2013) (0)
P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey (2015) (0)
Su1415 The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis (2016) (0)
targeting of gut bacterium attenuates alcoholic liver disease. (2019) (0)
698 Histological features associated with fibrosis progression occur in a particular subgroup of heavy drinkers (2006) (0)
Severe obesity increases death and dropout from liver waiting list: French liver transplant cohort (2020) (0)
Comparison of Binary Predictive Scoring Systems of Post-Hepatectomy Liver Failure: A Response. (2015) (0)
287 ICAM-1 AND VCAM-1 EXPRESSION IN HEPATOCYTE IS REGULATED BY NOD1 PATHWAY (2013) (0)
100 BASELINE MODELS HELP IN IDENTIFYING RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A MULTICENTER STUDY ON MORE THAN 600 PATIENTS (2012) (0)
Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282]. (2022) (0)
Editorial: when cirrhosis deserves haemodialysis—rethinking strategies. Authors’ reply (2019) (0)
Principes de prise en charge des complications des malades cirrhotiques [Managing the complications of cirrhosis]. (2005) (0)
Liver transplantation for severe alcoholic hepatitis saves lives (2012) (0)
Reply by Authors. (2022) (0)
Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (2019) (0)
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty (2022) (0)
Whole transcriptome analysis of ductular reaction from patients with alcoholic hepatitis. Similarities to ductular reaction in DDC mouse model (2017) (0)
Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation (2022) (0)
[Chronic alcohol consumption and progress of hepatic lesions]. (2009) (0)
[Overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis]. (2004) (0)
[Percutaneous nephrolithotomy]. (1985) (0)
[Laparoscopic treatment of recurrence and embolization failure of varicocele]. (1995) (0)
214 PREGNANCY IN WOMEN WITH PORTAL VEIN CAVERNOMA (PVC): MATERNAL AND FOETAL MANAGEMENT AND OUTCOME (2009) (0)
Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming. (2023) (0)
The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort) (2016) (0)
P957 FINAL ANALYSIS OF AETIOLOGY/COMORBIDITIES IN EUROPEAN PATIENTS FROM THE GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB) STUDY (2014) (0)
[Radiologic analysis of low back pain]. (1981) (0)
Standardising early liver transplantation for severe alcohol-related hepatitis - Authors' reply. (2022) (0)
Clinical Practice Guidelines : Management of alcohol-related liver disease q European Association for the Study of the Liver (2018) (0)
Évaluation pronostique de l’Acute On Chronic Liver Failure comme syndrome dynamique (2020) (0)
Reply to HEP-21-0216 "Acute Liver Injury due to Therapeutic Doses of Acetaminophen - Confounders must be ruled out!" (2021) (0)
Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study (2023) (0)
P0150 : Liver cirrhosis is independently associated with mortality in patients with bacterial endocarditis: Results of a case control multicenter study of 202 cases (2015) (0)
Time-of-day-dependent variation of the hepatic transcriptome and metabolome is disrupted in non-alcoholic fatty liver disease patients (2023) (0)
Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France (2016) (0)
[Contribution of tomodensitometry and echography to the study of salivary gland pathology]. (1983) (0)
Evolution and impact of obesity in patients on the liver transplant waiting list (2018) (0)
What's Hot in the Red Journal This Month (2015) (0)
Chapter 25. Alcoholic Liver Disease (2007) (0)
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial (2023) (0)
[Acute recurrent pancreatitis in a composite CFTR heterozygote and Spink1 heterozygote patient]. (2006) (0)
Lateral Approach for Lumbar Discography (1982) (0)
[The Roentgenological Check-up of Low-back Ache] (1980) (0)
345 DIAGNOSTIC VALUE OF LIVER INJURY BIOMARKERS, FIBROTEST (FT), STEATOTEST (ST), NASHTEST (NT) IN PATIENTS WITHOUT ADVANCED DISEASE UNDERGOING BARIATRIC SURGERY (2010) (0)
Mo1448 OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (0)
TIPS placement improves sarcopenia and modifies fat distribution: A monocentric retrospective study (2018) (0)
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease (2019) (0)
202 CIRRHOSIS IS A MAJOR PROGNOSTIC FACTOR OF SURVIVAL DIALYZED PATIENTS: THE NEPHRONORD NETWORK STUDY (2009) (0)
Contents Vol. 31, 1999 (1999) (0)
Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts (2020) (0)
Reply: To PMID 24677195. (2014) (0)
Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study) (2022) (0)
A Review of the Diagnosis and Treatment of Alcohol-Associated Liver Disease-Reply. (2021) (0)
Interventional Neuroradiology of Ear, Nose and Throat Conditions in the Neighbourhood of Neuronal Structures (1987) (0)
Effet of bariatric surgery in biopsy-proven NASH patients after 5 years (2018) (0)
Does Multiorgan Failure Impact Prognosis of Liver Transplantation in Patients with End-Stage Liver Disease? Results of a French Retrospective Multicenter Case-Control Study (2016) (0)
Conference Article (0)
MYCOPHENOLATE MOFETYL (MMF) THERAPY USED IN A PRIMARY IMMUNOSUPPRESSIVE REGIMEN FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION (OLT) (2004) (0)
A modelling approach to estimate alcohol-related liver morbidity and mortality in France (2022) (0)
Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer‐specific and overall mortality: A modeling approach (2022) (0)
Prevalence and Incidence of Subclinical Proximal Tubulopathy (SPT) over 96 Weeks in Chronic Hepatitis B (CHB) Patients Treated with Entecavir (ETV) or Tenofovir Disoproxil (TDF) without Renal Insufficiency (RI) or Hypophosphatemia during the Follow-up (2018) (0)
1161 A PROSPECTIVE STUDY OF ACETAMINOPHEN THERAPEUTIC MISADVENTURE: DURATION OF INTAKE AND HEAVY DRINKING ARE TWO KEY FACTORS (2010) (0)
[Managing the complications of cirrhosis]. (2005) (0)
765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION (2013) (0)
"Alcohol-associated liver disease: integrated management with alcohol use disorder". (2023) (0)
CORTICOSTEROIDS FOR ALCOHOLIC LIVER DISEASE: STRENGTH IN NUMBERS? (2002) (0)
1054 MODERATE AND EXCESSIVE ALCOHOL INTAKE IMPACT TRANSPLANT-FREE SURVIVAL: A LONGITUDINAL STUDY IN HCV CIRRHOTIC PATIENTS (2010) (0)
MRI Detection of Intramedullary Ischemia Due to Cervical Spondylosis (1989) (0)
A randomized trial comparing TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma (2023) (0)
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors (2022) (0)
Patients naïfs : traitement « à la carte » ? (2010) (0)
Treatment patterns and survival in patients with late-stage hepatocellular carcinoma in France: A retrospective database analysis. (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Philippe Mathurin?

Philippe Mathurin is affiliated with the following schools:

Philippe Mathurin's Academic­Influence.com Rankings

Philippe Mathurin's Degrees

Similar Degrees You Can Earn

Why Is Philippe Mathurin Influential?

Philippe Mathurin's Published Works

Published Works

What Schools Are Affiliated With Philippe Mathurin?

Philippe Mathurin's AcademicInfluence.com Rankings